Indications and uses
Helps prevent sunburn (Optional) If used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun
Neutrogena Pure and Free Baby Faces
- Manufacturer
- Johnson & Johnson Consumer Inc.
- Effective date
- 2019-12-12
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:51:58
Label at a glance#
ProductNeutrogena Pure and Free Baby Faces Ultra Gentle Sunscreen Broad Spectrum SPF45 Plus
Active ingredientTitanium Dioxide, Zinc Oxide
Label structure11 sections
Dosage and administration
apply generously 15 minutes before sun exposure reapply: after 80 minutes of swimming or sweating immediately after towel drying at least every 2 hours Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum value of SPF of 15 or higher and other sun protection measures including: Limit time in...
Storage and handling
Protect this product from excessive heat and direct sun May stain some fabrics
Contacts and useful links#
Websitewww.neutrogena.com
www.neutrogena.com
www.neutrogena.comLabel contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active ingredients
Titanium Dioxide 5.1%
Zinc Oxide 2.9%
Purpose
Sunscreen
Uses
- Helps prevent sunburn
- (Optional) If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun
Warnings
For external use only
OTC - DO NOT USE SECTION
Do not use on damaged or broken skin
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rinse with water to remove
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- apply generously 15 minutes before sun exposure
- reapply:
- after 80 minutes of swimming or sweating
- immediately after towel drying
- at least every 2 hours
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum value of SPF of 15 or higher and other sun protection measures including:
- Limit time in the sun, especially from 10 a.m. – 2 p.m.
- Wear long-sleeved shirts, pants hats, and sunglasses
- Children under 6 months: Ask a doctor
Other information
- Protect this product from excessive heat and direct sun
- May stain some fabrics
Inactive Ingredients
Aluminum Hydroxide, C12-15 Alkyl Benzoate, Carbomer, Cetyl Alcohol, Cetyl Dimethicone, Cetyl Hydroxyethylcellulose, Cetyl PEG/PPG-10/1 Dimethicone, Dimethicone, Dimethicone Crosspolymer , Dimethicone/Vinyl Dimethicone Crosspolymer, Disodium Phosphate, Ethylhexylglycerin, Glycerin, Hexyl Laurate, Hydrated Silica, Isopropyl Myristate, Magnesium Sulfate, Phenoxyethanol, Polyglyceryl-4 Isostearate, Silica, Sodium Hydroxide, Sodium Phosphate, Stearic Acid, Styrene/Acrylates Copolymer, riethoxycaprylylsilane, Trisiloxane, Water
Questions or comments?
Visit www.neutrogena.com or call toll-free 800-299-4786 or 215-273-8755 (collect)
SPL UNCLASSIFIED SECTION
Dist. by Neutrogena Corporation Los Angeles, CA 90045
PRINCIPAL DISPLAY PANEL - 73 mL Tube Carton
Neutrogena®
pure & free®
baby faces
ultra gentle cream
SUNSCREEN
Broad Spectrum
SPF 45+
pureSCREEN®
broad spectrum uva-uvb
TEAR FREE
100% naturally sourced sunscreens
hypoallergenic
water resistant (80 minutes)
#1 DERMATOLOGIST
RECOMMENDED SUNCARE
2.5 FL OZ (73mL)
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Titanium Dioxide | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| Titanium Dioxide | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| Zinc Oxide | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| Alkyl (C12-15) Benzoate | INACTIVE INGREDIENT | A9EJ3J61HQ | 1 | |
| Aluminum Hydroxide | INACTIVE INGREDIENT | 5QB0T2IUN0 | 1 | |
| Cetyl Alcohol | INACTIVE INGREDIENT | 936JST6JCN | 1 | |
| Dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| Ethylhexylglycerin | INACTIVE INGREDIENT | 147D247K3P | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Hexyl Laurate | INACTIVE INGREDIENT | 4CG9F9W01Q | 1 | |
| Hydrated Silica | INACTIVE INGREDIENT | Y6O7T4G8P9 | 1 | |
| Isopropyl Myristate | INACTIVE INGREDIENT | 0RE8K4LNJS | 1 | |
| Magnesium Sulfate | INACTIVE INGREDIENT | DE08037SAB | 1 | |
| Phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| Polyglyceryl-4 Isostearate | INACTIVE INGREDIENT | 820DPX33S7 | 1 | |
| Silicon Dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| sodium Phosphate | INACTIVE INGREDIENT | SE337SVY37 | 1 | |
| Sodium Phosphate, Dibasic, Anhydrous | INACTIVE INGREDIENT | 22ADO53M6F | 1 | |
| Stearic Acid | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| Triethoxycaprylylsilane | INACTIVE INGREDIENT | LDC331P08E | 1 | |
| Trisiloxane | INACTIVE INGREDIENT | 9G1ZW13R0G | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Neutrogena Pure and Free Baby Faces Ultra Gentle Sunscreen Broad Spectrum SPF45 Plus
- Titanium Dioxide and Zinc Oxide
- Titanium Dioxide
- Zinc Oxide
- Aluminum Hydroxide
- Alkyl (C12-15) Benzoate
- Cetyl Alcohol
- CETYL DIMETHICONE 25
- Dimethicone
- DIMETHICONE CROSSPOLYMER (450000 MPA.S AT 12% IN CYCLOPENTASILOXANE)
- Sodium Phosphate, Dibasic, Anhydrous
- Ethylhexylglycerin
- Glycerin
- Hexyl Laurate
- Hydrated Silica
- Isopropyl Myristate
- MAGNESIUM SULFATE, UNSPECIFIED FORM
- Phenoxyethanol
- Polyglyceryl-4 Isostearate
- Silicon Dioxide
- Sodium Hydroxide
- sodium Phosphate
- Stearic Acid
- Triethoxycaprylylsilane
- Trisiloxane
- Water
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 10812-420 | 10812-420-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EPIDURAL | ADJ PH | ||
| sodium Phosphate | SODIUM PHOSPHATE | SE337SVY37 | TABLET / ORAL | 16 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / INTRAMUSCULAR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, LIQUID FILLED / ORAL | 1.5 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SOLUTION / SUBCUTANEOUS | 0.11 %w/v | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SOFT TISSUE | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAMUSCULAR | 176 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION / INTRASYNOVIAL | 3 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRADERMAL | ADJ PH | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | TABLET / ORAL | 336 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | AEROSOL, FOAM / TOPICAL | ADJ PH | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1751 mg | ||
| sodium Phosphate | SODIUM PHOSPHATE | SE337SVY37 | INJECTION / INTRAMUSCULAR | 10.6 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INSERT / INTRAOCULAR | 0.02 mg | ||
| Magnesium Sulfate | MAGNESIUM SULFATE | DE08037SAB | TABLET / ORAL | 2.9 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVASCULAR | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| sodium Phosphate | SODIUM PHOSPHATE | SE337SVY37 | INJECTION / INTRAVENOUS | 10.6 mg | ||
| sodium Phosphate | SODIUM PHOSPHATE | SE337SVY37 | INJECTION, SOLUTION / INTRAMUSCULAR | 0.14 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 139.2 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RECTAL | NA | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRASPINAL | ADJ PH | ||
| Isopropyl Myristate | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OINTMENT / TOPICAL | 35 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | GEL / VAGINAL | 20 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVASCULAR | ADJ PH | ||
| sodium Phosphate | SODIUM PHOSPHATE | SE337SVY37 | INJECTION / ORAL | 10.35 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | CAPSULE, DELAYED RELEASE / ORAL | 43 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | AEROSOL, FOAM / TOPICAL | 0.09 %w/w | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | LOTION / TOPICAL | 1 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTABLE, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTERSTITIAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| Cetyl Alcohol | CETYL ALCOHOL | 936JST6JCN | LOTION / TOPICAL | 1140 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SOLUTION/ DROPS / TOPICAL | 0.14 %w/v | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | TABLET, COATED / ORAL | 42.4 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | CREAM / TOPICAL | 0.36 %w/w | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| Aluminum Hydroxide | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | TABLET / ORAL | 50 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| Cetyl Alcohol | CETYL ALCOHOL | 936JST6JCN | TABLET, COATED / ORAL | 0.25 mg | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | SOAP / TOPICAL | 6 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| Stearic Acid | STEARIC ACID | 4ELV7Z65AP | TABLET / BUCCAL | 6 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | GRANULE, FOR SUSPENSION / ORAL | ADJ PH | ||
| Isopropyl Myristate | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / TOPICAL | 65000 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 182b1083-1bd1-4162-a9a3-552e67b5c9c0 | 46b024a5-5af6-43ae-adb5-0340ec23d504 | 2020-05-07 | Warnings | 46b024a5-5af6-43ae-adb5-0340ec23d504 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.